sh-Oligopeptide-4 for Hair Regrowth

Created on 11/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

sh-Oligopeptide-4 is a cosmetic peptide explored for hair growth. Human hair evidence concerns mixtures and procedures that cannot isolate its contribution; reliable regrowth from the isolated ingredient is not established. Related scalp research addresses flaking rather than regrowth. Long-term scalp safety, dose, and maintenance schedules remain undefined; enhanced delivery adds uncertain exposure and contamination concerns. (Full Review)

Protocol

Established dose
No established isolated-ingredient dose
No controlled human hair trial establishes concentration, amount per scalp area, titration, or maximum dose.
Related scalp research
0.5 mg/mL every other day
Recombinant thymosin beta-4 alongside shampoo for four weeks; dermatitis protocol, not a validated hair-regrowth dose.
Timing and frequency
No evidence-based application schedule
No evidence establishes morning versus evening application or single versus split dosing.
Time to effect
Time to effect
No reliable isolated-ingredient onset
Mixture hair outcomes assessed after six months cannot establish a serum’s expected response.
Reduced Scalp Flaking
Four weeks
Improvement versus placebo with recombinant thymosin beta-4; equivalence to commercial sh-Oligopeptide-4 is unverified.

Benefits

Contraindications
  • Known allergy to the preparation
  • Application over known or suspected skin malignancy
Key Interactions
Theoretical (inferred from mechanism)
  • Barrier-disrupting procedures: Microneedling or injection.
  • Irritating scalp products: Concurrent alcohol-rich minoxidil solutions or exfoliating acids.

Risk & Side Effects

  • High:
  • Medium:
  • Low: Injection Pain
  • Speculative: Local Irritation or Allergy; Infection After Barrier-Breaking Delivery; Promotion of Existing Malignant Cells

Monitoring

Marker Target Why
Hair density at fixed scalp sites No established target; track change from baseline Intended efficacy outcome
Scalp redness, swelling, and pain No established target; track new or worsening symptoms Safety check affecting continued use

Cadence: Common practice, not a tested protocol: baseline; one month for tolerability; three and six months for photographs and hair measurements; earlier assessment for new symptoms.

Qualitative Assessment

  • Visible coverage: Matched photographs and styling alongside counts.
  • Symptoms and acceptability: Persistent itching, discomfort, and treatment burden.
  • Interpretability: Subjective improvement without consistent photographs or measurements remains uncertain, especially when other treatments change.